Status:
COMPLETED
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Lead Sponsor:
Bayer
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
Eligibility Criteria
Inclusion
- Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria
- Body surface area affected by atopic dermatitis at or less than 15% at start of treatment
Exclusion
- Pregnancy and breast-feeding
- Conditions that may pose a threat to the patient or effect the outcome of the study
- Wide-spread atopic dermatitis (AD) requiring systemic treatment
- Immuno-compromized conditions
- At least 2 weeks after local AD treatment and treatment with systemic antibiotics
- At least 1 month after systemic AD treatment
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT01228513
Start Date
November 1 2010
End Date
April 1 2012
Last Update
January 21 2016
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim, California, United States, 92801
2
Honolulu, Hawaii, United States, 96813
3
Boise, Idaho, United States, 83704
4
Chicago, Illinois, United States, 60612